Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GDUFA: Review Costs Continued To Climb Once Formal Review Goals Began

Executive Summary

Generic drug reviews during the first year of formal review goals cost 70% more than during GDUFA's inaugural year.


Related Content

ANDA Approvals, Submissions Decline With New Review Goal Coming
Woodcock's Legacy: CDER Organizational Improvements
Generic User Fee Talks Reach 'Final Wording' But Still Not Done
ANDA User Fees Offer Sponsor Relief, But More Facility Pain
FDA Construction Plans Need 'Innovative Financing Options'
ANDA Approval Speed-Up Leaves Sponsors With Less Margin For Error
ANDA Sponsors: Update Your FDA Contacts List
Generic Drug Review Costs Still Largely Non-Personnel Related
GDUFA Performance Goals For Fiscal Years 2013-2017





Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts